company background image
GBY logo

Sangamo Therapeutics DB:GBY Stock Report

Last Price

€2.16

Market Cap

€493.9m

7D

14.6%

1Y

614.0%

Updated

23 Dec, 2024

Data

Company Financials +

Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €493.9m

GBY Stock Overview

A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More details

GBY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Sangamo Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sangamo Therapeutics
Historical stock prices
Current Share PriceUS$2.16
52 Week HighUS$2.92
52 Week LowUS$0.25
Beta1.18
1 Month Change18.60%
3 Month Change170.04%
1 Year Change613.95%
3 Year Change-70.88%
5 Year Change-71.49%
Change since IPO-80.37%

Recent News & Updates

Recent updates

Shareholder Returns

GBYDE BiotechsDE Market
7D14.6%-3.5%-2.0%
1Y614.0%-14.7%6.9%

Return vs Industry: GBY exceeded the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: GBY exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is GBY's price volatile compared to industry and market?
GBY volatility
GBY Average Weekly Movement26.0%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: GBY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: GBY's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1995405Sandy Macraewww.sangamo.com

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.

Sangamo Therapeutics, Inc. Fundamentals Summary

How do Sangamo Therapeutics's earnings and revenue compare to its market cap?
GBY fundamental statistics
Market cap€493.92m
Earnings (TTM)-€129.23m
Revenue (TTM)€50.12m

9.9x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBY income statement (TTM)
RevenueUS$52.29m
Cost of RevenueUS$129.85m
Gross Profit-US$77.56m
Other ExpensesUS$57.28m
Earnings-US$134.84m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.65
Gross Margin-148.33%
Net Profit Margin-257.86%
Debt/Equity Ratio0%

How did GBY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangamo Therapeutics, Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gregory HarrisonBofA Global Research
Jonathan AschoffBrean Capital